Robert Goodman - Icad Director

ICAD -  USA Stock  

USD 3.67  0.18  5.16%

  Director
Dr. Robert L. Goodman, M.D., is the Independent Director of iCAD Inc. He is an experienced and accomplished medical executive. He was the founding Chair of the Department of Radiation Oncology at the University of Pennsylvania and between 19771991 served as the Henry Pancoast Professor and Chair. During part of that period he also served as the Chair of the Clinical Practices Executive Committee as well as Interim Executive Director of the Hospital of the University of Pennsylvania. He subsequently served as Senior Vice President and Corporationrationrate Medical Director at US Healthcare prior to its Sale to Aetna, and later in the 1990s as Senior Vice President at Universal Health Services, a forprofit hospital chain with central offices in King of Prussia, PA. He briefly served as the Brady Professor and Chair of Radiation Oncology at the Hahnemann University prior to its takeover by Drexel University. From 1998, almost to the present, he was the Chair of Radiation Oncology at Saint Barnabas Medical Center in Livingston, NJ. Dr. Goodman is now the Senior Advisor to the President for Clinical Affairs at Thomas Jefferson University. He serves as a resource to the Jefferson leadership team to assist with facilitating the achievement of the multiple milestones and organizational changes required to meet their goals. He also serves as Professor of the Department of Radiation Oncology at Thomas Jefferson University.
Age: 73  Director Since 2014      
603 882 5200  https://www.icadmed.com

Robert Goodman Latest Insider Activity

Tracking and analyzing the buying and selling activities of Robert Goodman against Icad stock is an integral part of due diligence when investing in Icad. Robert Goodman insider activity provides valuable insight into whether Icad is net buyers or sellers over its current business cycle. Note, Icad insiders must abide by specific rules, including filing SEC forms every time they buy or sell Icad'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Goodman over a year ago via Macroaxis 
Icad exotic insider transaction detected

Icad Management Efficiency

Icad Inc has return on total asset (ROA) of (11.39) % which means that it has lost $11.39 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (29.19) %, meaning that it created substantial loss on money invested by shareholders. Icad management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of May 26, 2022, Return on Average Assets is expected to decline to -0.18. In addition to that, Return on Average Equity is expected to decline to -0.24. Icad Goodwill and Intangible Assets are projected to decrease significantly based on the last few years of reporting. The past year's Goodwill and Intangible Assets were at 9.04 Million. The current year Asset Turnover is expected to grow to 0.62, whereas Current Assets are forecasted to decline to about 42.9 M.
The company currently holds 1.16 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Icad Inc has a current ratio of 3.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Icad until it has trouble settling it off, either with new capital or with free cash flow. So, Icad's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Icad Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Icad to invest in growth at high rates of return. When we think about Icad's use of debt, we should always consider it together with cash and equity.
Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Icad Inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine Icad value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Showing few of many executives

DIRECTOR Since

Gayle WellbornHealthequity
2017
Julie GerberdingCerner Corp
2017
Yancey SpruillAllscripts Hlthcare
2016
George RiedelCerner Corp
2019
Ralph ThurmanAllscripts Hlthcare
2012
Kenneth SametEvolent Health
2015
Michael LeavittHealthequity
2010
Ian SacksHealthequity
2004
Gerald BisbeeCerner Corp
1988
Halsey WiseCerner Corp
2019
P GarrisonAllscripts Hlthcare
2015
Michael KirshbaumEvolent Health
2013
John DalyCarecloud
2013
Mara AspinallAllscripts Hlthcare
2017
Frank CorvinoHealthequity
2014
Bruce FeltEvolent Health
2015
John GreischCerner Corp
2019
Gregory GarrisonAllscripts Hlthcare
2015
Evelyn DilsaverHealthequity
N/A
Michael KlaykoAllscripts Hlthcare
2014
Jonathan JudgeAllscripts Hlthcare
2016
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. Icad operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 136 people. Icad Inc (ICAD) is traded on NASDAQ Exchange in USA. It is located in 98 Spit Brook Road and employs 136 people. Icad is listed under Medical Equipment category by Fama And French industry classification.

Icad Inc Leadership Team

Elected by the shareholders, the Icad's board of directors comprises two types of representatives: Icad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icad. The board's role is to monitor Icad's management team and ensure that shareholders' interests are well served. Icad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icad's outside directors are responsible for providing unbiased perspectives on the board's policies.
Elliot Sussman, Independent Director
Andrew Sassine, Director
Kevin Burns, President, CFO, COO, Treasurer and Secretary
Somu Subramaniam, Independent Director
Rakesh Patel, Director
Steven Rappaport, Independent Director
Jonathan Go, Sr. VP of RandD
Zack Kubow, IR Contact Officer
Scott Areglado, Vice President Controller
Michael Klein, Director
Stacey Stevens, Sr. VP of Marketing and Strategy
Anthony Ecock, Independent Director
Rachel Brem, Independent Director
Susan Wood, Director
Richard Christopher, CFO, Executive Vice President
Lawrence Howard, Chairman of the Board
Kenneth Ferry, CEO and Director
Robert Goodman, Director

Icad Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Icad Investors Sentiment

The influence of Icad's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Icad. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Icad Implied Volatility

    
  59.54  
Icad's implied volatility exposes the market's sentiment of Icad Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Icad's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Icad stock will not fluctuate a lot when Icad's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Icad in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Icad's short interest history, or implied volatility extrapolated from Icad options trading.

Current Sentiment - ICAD

Icad Inc Investor Sentiment

Most of Macroaxis users are currently bullish on Icad Inc. What is your judgment towards investing in Icad Inc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Icad Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Icad Inc information on this page should be used as a complementary analysis to other Icad's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Icad Stock analysis

When running Icad Inc price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Icad Inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine Icad value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.